文献速递消化系统肿瘤

补充海洋ω-3脂肪酸对结直肠腺瘤和锯齿状息肉风险的影响:VITAL随机临床试验的预设辅助研究

Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

结果显示ω-3组与对照组结直肠传统腺瘤(OR 0.98, 95%CI 0.83-1.15)和锯齿状息肉(OR 1.05, 95%CI 0.84-1.29)风险均无显著差异。

要点

  • 每日1g海洋ω-3补充未降低结直肠腺瘤或锯齿状息肉风险。
  • 非洲裔人群显示潜在获益(OR 0.59, 95%CI 0.35-1.00),需进一步验证。

核心结论

  • 每日补充1g海洋ω-3脂肪酸未能降低结直肠癌前病变(传统腺瘤和锯齿状息肉)的风险。
  • 基线ω-3水平低或非洲裔人群的潜在获益需进一步确认。

研究设计与样本

  • VITAL随机对照试验的预设辅助研究,采用意向性分析。
  • 干预为每日1g海洋ω-3脂肪酸(EPA 460mg,DHA 380mg),中位随访5.3年(范围3.8-6.1年)。

主要发现

  • ω-3组发生294例传统腺瘤,对照组301例(多变量OR 0.98, 95%CI 0.83-1.15)。
  • ω-3组发生174例锯齿状息肉,对照组167例(OR 1.05, 95%CI 0.84-1.29)。
  • 按息肉大小、位置、数量或组织学亚组分析均未发现显著关联。

临床怎么用

  • 不推荐常规使用海洋ω-3脂肪酸补充剂来预防结直肠腺瘤或锯齿状息肉。
  • 对于基线ω-3水平低或非洲裔个体,补充的潜在获益需个体化评估并等待进一步验证。

局限性

  • 研究为辅助分析,部分息肉诊断依赖随访问卷并仅对部分病例进行记录确认。
  • 干预持续时间有限(中位5.3年),长期效果未知。
  • 亚组分析(如ω-3指数低、非洲裔)为探索性,需独立验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Marine ω-3 fatty acid has been suggested to protect against colorectal cancer. OBJECTIVE: To assess the effect of daily marine ω-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. DESIGN, SETTING, AND PARTICIPANTS: This study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL (Vitamin D and Omega-3 Trial). An intention-to-treat analysis was used to examine the effect of daily marine ω-3 supplements among 25 871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017. INTERVENTIONS: Marine ω-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. MAIN OUTCOMES AND MEASURES: Risk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. RESULTS: The demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the ω-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the ω-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the ω-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine ω-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of ω-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P = .03 for interaction by ω-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P = .11 for interaction). CONCLUSIONS AND RELEVANCE: Supplementation with marine ω-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A potential benefit of this supplementation for individuals with low baseline ω-3 levels or for African American persons requires further confirmation. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01169259.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Song M, Lee IM, Manson JE, et al. Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 31750855. doi:10.1001/jamaoncol.2019.4587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。